Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,755

Document Document Title
WO/2023/156461A1
The present invention relates to the field of the synthesis of chemical compounds having a dihydrobenzoxepine structure. In particular, the invention relates to a process for preparing chemical compounds comprising a 2,5-dihydro-1-benzox...  
WO/2023/110132A1
The invention is in the field of fragrances and relates to novel oxa-macrocyclic fragrance compounds according to general formula (I) with a musk-based note and improved biological degradability and further with improved chemical stabili...  
WO/2023/067043A9
Improved methods of making amberketal and amberketal homologues and compositions comprising same, improved squalene-hopene cyclase (SHC) enzymes to be used in said methods, nucleic acid constructs and vectors encoding said enzymes, and h...  
WO/2023/089158A1
Disclosed are oxa macrocyclic ketones of formula (I) possessing musky, powdery, nitro musk odor characteristics.  
WO/2023/067044A1
The disclosure relates to sesquiterpene homologues, their use as fragrance and a method of their production.  
WO/2023/038093A1
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the ...  
WO/2023/027336A1
The present specification relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.  
WO/2023/026884A1
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...  
WO/2023/026051A1
Methods for staining mitochondria are disclosed involving using a composition containing a cationic species of the formula: (I) wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, S...  
WO/2023/001323A1
The present invention relates to a lipidoid of general formula I, wherein X is selected from -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C≡...  
WO/2022/263702A1
Pladienolide B for use in the treatment of glioblastoma.  
WO/2022/243300A1
The present invention concerns a composition of matter comprising a) 0.5 to 98.8% w/w of (Z)-oxacyclohexadec- 12-en-2-one; b) 0.1 to 10% w/w of (E)-oxacyclohexadec-12-en-2-one; c) 0 to 10% w/w of (E)-oxacyclohexadec-13-en-2-one; and d) 0...  
WO/2022/217265A1
Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R1, R2, X1, X2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, and Y8) are as disclosed herein. Also provided herein are ph...  
WO/2022/207923A1
Substituted lactones and the polymers prepared by ring opening thereof are disclosed, likewise the processes for producing the lactones and polymers and the use thereof, in particular in electrochemical applications, in particular in ele...  
WO/2022/191314A1
The present invention makes it possible to produce adipic acid at a high selectivity without emitting dinitrogen monoxide by using a 3-hydroxyadipic acid 3,6-lactone composition as a starting material, the composition containing 3 to 30 ...  
WO/2022/192384A1
Provided herein are biosynthetic methods for producing lactones, such as macrocyclic lactones, from fatty acids. The lactones produced using and/or during the biosynthetic methods are also provided.  
WO/2022/179476A1
Disclosed in the present invention are a series of fused polycyclic substituted 5-carboxylic acid thienopyrimidine dione compounds and the use thereof. Specifically disclosed are a compound represented by formula (II) and a pharmaceutica...  
WO/2022/162471A1
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.  
WO/2022/165398A1
In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical compositi...  
WO/2022/134297A1
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...  
WO/2022/133031A1
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.  
WO/2022/040788A1
Anti -cancer, chemotherapeutic, or antiproliferative compositions comprising, as an active ingredient, a compound of formula (I0), or a salt, or prodrug thereof: and an anti-cancer, chemotherapeutic, or antiproliferative compound (A) or ...  
WO/2021/249008A1
Disclosed in the present invention is a method for preparing epsilon-caprolactone by using an in-situ peroxide. The method efficiently utilizes an in-situ peroxide obtained in a process of oxidizing alcohol by oxygen to oxidize cyclohexa...  
WO/2021/209482A1
An enzyme-mediated method for the production of Amberketal and Amberketal homologues, the products of said method, and uses of said products.  
WO/2021/208918A1
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...  
WO/2021/188772A1
The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of a K+/Cl- cotransporter (Kcc2/KCC2) gene e...  
WO/2021/122945A1
The present invention concerns a composition of matter comprising a) 0.5 to 85% w/w of (Z)-oxacyclohexadec-12-en-2-one; b) 0.5 to 30% w/w of (E)-oxacyclohexadec-12-en-2-one; c) 0 to 30% w/w of (E)-oxacyclohexadec-13-en-2-one; and d) 0.5 ...  
WO/2021/103798A1
Disclosed is a method for preparing a lactone compound, the method comprising performing an oxidation reaction on a cyclic ketone using molecular oxygen in the presence of an organic nitrogen-oxygen radical precursor, a free radical init...  
WO/2021/104529A1
The present disclosure relates to the field of pharmaceutical chemistry, and specifically relates to a use of a brefeldin A ester derivative in inhibiting tumor proliferation activity, the structure of said brefeldin A ester derivative b...  
WO/2021/047292A1
Disclosed in the present invention is a novel method for co-production of a high-efficiency carboxylic acid based on oxygen oxidation and ε-caprolactone, i.e., under the catalysis of a catalyst, oxidizing cyclohexanone to ε-caprolacton...  
WO/2021/037806A1
The presently claimed invention is directed to 2,2,6-trimethyl-4,5-dihydro-3H-oxepine and its use to impart an aroma impression to a composition. The presently claimed invention also relates to a method of imparting such an aroma impress...  
WO/2021/038292A1
Compounds that are inhibitors of p38alpha and centrally available are described.  
WO/2020/254507A1
Compounds of general Formula (I) wherein the elements A, L, R1 and R2 have a defined meaning, and their medical and non-medical use.  
WO/2020/193681A1
The present invention relates to derivatives of 10-methylene lipids, their preparation and their use.  
WO/2020/185712A1
The present disclosure relates to methods of alleviating a symptom of, treating, or preventing a sleep disorder by administering a ligand of α2δ-1 auxiliary subunit of voltage-gated calcium channels, a ligand of α2δ-2 auxiliary subun...  
WO/2020/090700A1
The present invention addresses the problem of providing an ynone compound useful for the inducement of an endoplasmic reticulum stress response. The problem can be solved by an ynone compound represented by formula (1) [in the formula, ...  
WO/2020/084005A1
The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such comp...  
WO/2020/063999A1
Disclose herein are mono halogen or methyl-substituted 5-HT 2B antagonist compounds, which have been found with increased binding activity to 5-HT 2B receptor due to the substitution of halogen or methyl, and the method of using the comp...  
WO/2020/055113A1
The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosu...  
WO/2020/023356A1
The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of prolif...  
WO/2019/232639A1
The present invention provides a new compound of formula (II), extracted from Chaetomorpha Cannabina seaweed. (II) The methods for extraction from the seaweed, the fractionation and isolation of the compound, the determination of the ste...  
WO/2019/207246A1
The present invention relates to a method for olefin metathesis, which comprises placing in contact: - at least one olefin, - at least one metathesis catalyst selected from the ruthenium alkylidene complexes comprising two imidazoline-2-...  
WO/2019/200100A1
The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, ...  
WO/2019/199667A2
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, pa...  
WO/2019/171278A1
The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particul...  
WO/2019/158485A1
The invention provides a method for synthesizing musk macrocycles comprising contacting an easily accessible diene starting materials bearing a Z-olefin moiety and performing a ring closing metathesis reaction in the presence of a Group ...  
WO/2019/144132A1
Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen rece...  
WO/2019/124523A1
In the present invention, an efficacious therapy for glaucoma is discovered and provided as a medicine. A combination of the present invention, in particular a combination of 2-propanyl 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E, 3R)-4-(2, 5-diflu...  
WO/2019/113019A2
This invention relates generally to the synthesis of E-macrocycles using stereoretentive ruthenium olefin metathesis catalysts supported by dithioiate ligands. Macrocycles were generated with excellent selectivity (>99% E) and in moderat...  
WO/2019/104850A1
Disclosed is a method for preparing a lactone compound, for which a cyclic ketone compound serves as a raw material; in an oxygen-containing atmosphere, a cyclic organic nitroxide free radical serves as a catalyst, and a certain amount o...  

Matches 1 - 50 out of 1,755